IDEXX Laboratories Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
IDEXX Laboratories yıllık ortalama 13.1% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 12% annual. Gelirler growing yılda ortalama 9.8% oranında artmaktadır. IDEXX Laboratories'in özkaynak karlılığı 53.5% ve net marjı 22.5%'dir.
Anahtar bilgiler
13.1%
Kazanç büyüme oranı
13.9%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | 8.9% |
| Gelir büyüme oranı | 9.8% |
| Özkaynak getirisi | 53.5% |
| Net Marj | 22.5% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
IDEXX Laboratories nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 3,845 | 866 | 947 | 214 |
| 30 Jun 24 | 3,785 | 846 | 934 | 208 |
| 31 Mar 24 | 3,725 | 867 | 925 | 199 |
| 31 Dec 23 | 3,661 | 845 | 902 | 191 |
| 30 Sep 23 | 3,588 | 823 | 888 | 183 |
| 30 Jun 23 | 3,514 | 791 | 877 | 183 |
| 31 Mar 23 | 3,431 | 699 | 858 | 259 |
| 31 Dec 22 | 3,367 | 679 | 851 | 255 |
| 30 Sep 22 | 3,340 | 670 | 848 | 257 |
| 30 Jun 22 | 3,309 | 664 | 840 | 249 |
| 31 Mar 22 | 3,274 | 735 | 821 | 164 |
| 31 Dec 21 | 3,215 | 745 | 796 | 161 |
| 30 Sep 21 | 3,135 | 757 | 770 | 154 |
| 30 Jun 21 | 3,047 | 728 | 777 | 152 |
| 31 Mar 21 | 2,858 | 674 | 739 | 146 |
| 31 Dec 20 | 2,707 | 582 | 735 | 141 |
| 30 Sep 20 | 2,591 | 497 | 717 | 138 |
| 30 Jun 20 | 2,475 | 460 | 674 | 134 |
| 31 Mar 20 | 2,457 | 437 | 681 | 135 |
| 31 Dec 19 | 2,407 | 428 | 669 | 133 |
| 30 Sep 19 | 2,351 | 423 | 657 | 128 |
| 30 Jun 19 | 2,291 | 407 | 642 | 123 |
| 31 Mar 19 | 2,252 | 390 | 638 | 120 |
| 31 Dec 18 | 2,213 | 377 | 632 | 118 |
| 30 Sep 18 | 2,170 | 330 | 621 | 117 |
| 30 Jun 18 | 2,117 | 307 | 610 | 115 |
| 31 Mar 18 | 2,045 | 284 | 596 | 112 |
| 31 Dec 17 | 1,969 | 263 | 575 | 109 |
| 30 Sep 17 | 1,906 | 277 | 561 | 106 |
| 30 Jun 17 | 1,862 | 263 | 547 | 104 |
| 31 Mar 17 | 1,820 | 245 | 534 | 102 |
| 31 Dec 16 | 1,775 | 222 | 522 | 101 |
| 30 Sep 16 | 1,732 | 214 | 516 | 101 |
| 30 Jun 16 | 1,690 | 202 | 502 | 100 |
| 31 Mar 16 | 1,637 | 192 | 493 | 99 |
| 31 Dec 15 | 1,602 | 192 | 482 | 100 |
| 30 Sep 15 | 1,554 | 174 | 475 | 99 |
| 30 Jun 15 | 1,531 | 182 | 467 | 99 |
| 31 Mar 15 | 1,508 | 182 | 457 | 100 |
| 31 Dec 14 | 1,486 | 182 | 448 | 98 |
| 30 Sep 14 | 1,488 | 199 | 435 | 96 |
| 30 Jun 14 | 1,443 | 193 | 422 | 93 |
| 31 Mar 14 | 1,405 | 190 | 409 | 89 |
| 31 Dec 13 | 1,377 | 188 | 401 | 88 |
Kaliteli Kazançlar: IDXX yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: IDXX 'nin mevcut net kar marjları (22.5%) geçen yılın (22.9%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IDXX şirketinin kazancı son 5 yılda yılda 13.1% oranında arttı.
Büyüme Hızlandırma: IDXX 'un son bir yıldaki kazanç büyümesi ( 5.3% ) 5 yıllık ortalamasının ( 13.1% /yıl) altındadır.
Kazançlar vs. Sektör: IDXX geçen yılki kazanç büyümesi ( 5.3% ) Medical Equipment sektörünün 10.4% performansını geride bırakmadı.
Özkaynak Getirisi
Yüksek ROE: IDXX 'nin Özsermaye Getirisi ( 53.5% ) ödenmemiş olarak değerlendirilmektedir.